Johnson & Johnson
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 78.74B | 79.99B | 85.16B | 88.82B | 94.19B | 6.0% | |
| Cost of Revenue | (23.40B) | (24.60B) | (26.55B) | (27.47B) | (30.26B) | 10.1% | |
Gross Profit | 55.34B | 55.39B | 58.61B | 61.35B | 63.94B | 4.2% | |
| Operating Expenses | |||||||
| Research & Development | (14.28B) | (14.13B) | (15.09B) | (17.23B) | (14.66B) | -14.9% | |
| Selling, General & Administrative | (20.12B) | (20.25B) | (20.11B) | (21.97B) | (23.68B) | 7.8% | |
| Depreciation & Amortization | (7.39B) | (6.97B) | (7.49B) | (7.34B) | (7.50B) | 2.2% | |
Operating Income (EBIT) | 20.94B | 21.01B | 23.41B | 22.15B | 25.60B | 15.6% | |
| Non-Operating Items | |||||||
| Interest Income | 53.00M | 490.00M | 1.26B | 1.33B | 1.06B | -20.7% | |
| Interest Expense | (183.00M) | (276.00M) | (772.00M) | (755.00M) | (971.00M) | 28.6% | |
| Other Income/Expenses (Net) | -1.76B | -1.65B | -8.35B | -5.46B | 6.99B | -227.9% | |
Income Before Tax | 19.18B | 19.36B | 15.06B | 16.69B | 32.58B | 95.2% | |
| Income Tax Expense | (1.38B) | (2.99B) | (1.74B) | (2.62B) | (5.78B) | 120.4% | |
Net Income | 20.88B | 17.94B | 35.15B | 14.07B | 26.80B | 90.6% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $8 | $7 | $14 | $6 | $11 | 88.9% | |
| Weighted Avg Shares Outstanding | 2.63B | 2.61B | 2.53B | 2.41B | 2.43B | 0.9% | |
| Weighted Avg Shares Outstanding (Diluted) | 2.67B | 2.66B | 2.56B | 2.43B | 2.43B | 0.0% | |
EBITDA | 26.75B | 26.61B | 23.32B | 24.78B | 41.05B | 65.7% |
Explore JNJ
JNJ in the Healthcare
Mega Cap